Early arteriovenous fistula failure associated with mortality and major adverse cardiovascular events in patients undergoing incident hemodialysis.

Early arteriovenous fistula failure cardiovascular disease hemodialysis major adverse cardiovascular events mortality

Journal

The journal of vascular access
ISSN: 1724-6032
Titre abrégé: J Vasc Access
Pays: United States
ID NLM: 100940729

Informations de publication

Date de publication:
05 Dec 2023
Historique:
medline: 6 12 2023
pubmed: 6 12 2023
entrez: 6 12 2023
Statut: aheadofprint

Résumé

Arteriovenous fistula (AVF) patency is important for patients undergoing hemodialysis. The association between early AVF failure and the prognosis, including all-cause mortality and major adverse cardiovascular events (MACE), has not been fully investigated. The present study was performed to investigate the association between early AVF failure and 3-year mortality, cardiovascular disease (CVD) mortality, and MACE. We analyzed 358 patients who started hemodialysis in our institution from October 2008 to February 2020. We defined early AVF failure as cases requiring percutaneous transluminal angioplasty or reoperation within 1 year after AVF surgery. The patients were divided into two groups according to the presence or absence of early AVF failure, and the prognosis of each group was examined. The association between early AVF failure and outcomes (3-year all-cause mortality, CVD mortality, and MACE) was determined using Cox proportional hazards regression analysis. During the 3-year follow-up, 75 (20.9%) patients died (cardiovascular death: Early AVF failure was associated with an increased risk of 3-year all-cause mortality, CVD mortality, and MACE.

Sections du résumé

BACKGROUND UNASSIGNED
Arteriovenous fistula (AVF) patency is important for patients undergoing hemodialysis. The association between early AVF failure and the prognosis, including all-cause mortality and major adverse cardiovascular events (MACE), has not been fully investigated. The present study was performed to investigate the association between early AVF failure and 3-year mortality, cardiovascular disease (CVD) mortality, and MACE.
METHODS UNASSIGNED
We analyzed 358 patients who started hemodialysis in our institution from October 2008 to February 2020. We defined early AVF failure as cases requiring percutaneous transluminal angioplasty or reoperation within 1 year after AVF surgery. The patients were divided into two groups according to the presence or absence of early AVF failure, and the prognosis of each group was examined. The association between early AVF failure and outcomes (3-year all-cause mortality, CVD mortality, and MACE) was determined using Cox proportional hazards regression analysis.
RESULTS UNASSIGNED
During the 3-year follow-up, 75 (20.9%) patients died (cardiovascular death:
CONCLUSIONS UNASSIGNED
Early AVF failure was associated with an increased risk of 3-year all-cause mortality, CVD mortality, and MACE.

Identifiants

pubmed: 38053252
doi: 10.1177/11297298231215106
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11297298231215106

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Aiko Okubo (A)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Toshiki Doi (T)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.
Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.

Yumi Yamada (Y)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Kenichi Morii (K)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.
Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.

Yoshiko Nishizawa (Y)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Kazuomi Yamashita (K)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Yasuhiro Fudaba (Y)

Department of Surgery, Ichiyokai Harada Hospital, Hiroshima, Japan.

Kenichiro Shigemoto (K)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Sonoo Mizuiri (S)

Department of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.

Koji Usui (K)

Ichiyokai Ichiyokai Clinic, Hiroshima, Japan.

Michiko Arita (M)

Ichiyokai East Clinic, Hiroshima, Japan.

Takayuki Naito (T)

Ichiyokai Yokogawa Clinic, Hiroshima, Japan.

Takao Masaki (T)

Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.

Classifications MeSH